These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34534488)
1. Efficacy of a family-based cardiovascular risk reduction intervention in individuals with a family history of premature coronary heart disease in India (PROLIFIC): an open-label, single-centre, cluster randomised controlled trial. Jeemon P; Harikrishnan S; Ganapathi S; Sivasankaran S; Binukumar B; Padmanabhan S; Tandon N; Prabhakaran D Lancet Glob Health; 2021 Oct; 9(10):e1442-e1450. PubMed ID: 34534488 [TBL] [Abstract][Full Text] [Related]
2. A PROgramme of Lifestyle Intervention in Families for Cardiovascular risk reduction (PROLIFIC Study): design and rationale of a family based randomized controlled trial in individuals with family history of premature coronary heart disease. Jeemon P; Harikrishnan S; Sanjay G; Sivasubramonian S; Lekha TR; Padmanabhan S; Tandon N; Prabhakaran D BMC Public Health; 2017 Jan; 17(1):10. PubMed ID: 28056897 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial. Groenewegen A; Zwartkruis VW; Rienstra M; Zuithoff NPA; Hollander M; Koffijberg H; Oude Wolcherink M; Cramer MJ; van der Schouw YT; Hoes AW; Rutten FH; de Boer RA Lancet Public Health; 2024 Feb; 9(2):e88-e99. PubMed ID: 38134944 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. He J; Ouyang N; Guo X; Sun G; Li Z; Mu J; Wang DW; Qiao L; Xing L; Ren G; Zhao C; Yang R; Yuan Z; Wang C; Shi C; Liu S; Miao W; Li G; Chen CS; Sun Y; Lancet; 2023 Mar; 401(10380):928-938. PubMed ID: 36871573 [TBL] [Abstract][Full Text] [Related]
5. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T; Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738 [TBL] [Abstract][Full Text] [Related]
7. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Xavier D; Gupta R; Kamath D; Sigamani A; Devereaux PJ; George N; Joshi R; Pogue J; Pais P; Yusuf S Lancet Diabetes Endocrinol; 2016 Mar; 4(3):244-253. PubMed ID: 26857999 [TBL] [Abstract][Full Text] [Related]
8. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial. Osborn D; Burton A; Hunter R; Marston L; Atkins L; Barnes T; Blackburn R; Craig T; Gilbert H; Heinkel S; Holt R; King M; Michie S; Morris R; Morris S; Nazareth I; Omar R; Petersen I; Peveler R; Pinfold V; Walters K Lancet Psychiatry; 2018 Feb; 5(2):145-154. PubMed ID: 29396118 [TBL] [Abstract][Full Text] [Related]
9. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Schwalm JD; McCready T; Lopez-Jaramillo P; Yusoff K; Attaran A; Lamelas P; Camacho PA; Majid F; Bangdiwala SI; Thabane L; Islam S; McKee M; Yusuf S Lancet; 2019 Oct; 394(10205):1231-1242. PubMed ID: 31488369 [TBL] [Abstract][Full Text] [Related]
10. Secondary prevention with a structured semi-interactive stroke prevention package in INDIA (SPRINT INDIA): a multicentre, randomised controlled trial. SPRINT INDIA trial collaborators Lancet Glob Health; 2023 Mar; 11(3):e425-e435. PubMed ID: 36796986 [TBL] [Abstract][Full Text] [Related]
11. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM; Lancet; 2022 Oct; 400(10359):1195-1205. PubMed ID: 36216006 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a lifestyle intervention led by female community health volunteers versus usual care in blood pressure reduction (COBIN): an open-label, cluster-randomised trial. Neupane D; McLachlan CS; Mishra SR; Olsen MH; Perry HB; Karki A; Kallestrup P Lancet Glob Health; 2018 Jan; 6(1):e66-e73. PubMed ID: 29241617 [TBL] [Abstract][Full Text] [Related]
13. Family-led rehabilitation after stroke in India (ATTEND): a randomised controlled trial. ATTEND Collaborative Group Lancet; 2017 Aug; 390(10094):588-599. PubMed ID: 28666682 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Moll van Charante EP; Richard E; Eurelings LS; van Dalen JW; Ligthart SA; van Bussel EF; Hoevenaar-Blom MP; Vermeulen M; van Gool WA Lancet; 2016 Aug; 388(10046):797-805. PubMed ID: 27474376 [TBL] [Abstract][Full Text] [Related]
15. Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Näslund U; Ng N; Lundgren A; Fhärm E; Grönlund C; Johansson H; Lindahl B; Lindahl B; Lindvall K; Nilsson SK; Nordin M; Nordin S; Nyman E; Rocklöv J; Vanoli D; Weinehall L; Wennberg P; Wester P; Norberg M; Lancet; 2019 Jan; 393(10167):133-142. PubMed ID: 30522919 [TBL] [Abstract][Full Text] [Related]
16. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Taheri S; Zaghloul H; Chagoury O; Elhadad S; Ahmed SH; El Khatib N; Amona RA; El Nahas K; Suleiman N; Alnaama A; Al-Hamaq A; Charlson M; Wells MT; Al-Abdulla S; Abou-Samra AB Lancet Diabetes Endocrinol; 2020 Jun; 8(6):477-489. PubMed ID: 32445735 [TBL] [Abstract][Full Text] [Related]
17. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Sánchez-de-la-Torre M; Sánchez-de-la-Torre A; Bertran S; Abad J; Duran-Cantolla J; Cabriada V; Mediano O; Masdeu MJ; Alonso ML; Masa JF; Barceló A; de la Peña M; Mayos M; Coloma R; Montserrat JM; Chiner E; Perelló S; Rubinós G; Mínguez O; Pascual L; Cortijo A; Martínez D; Aldomà A; Dalmases M; McEvoy RD; Barbé F; Lancet Respir Med; 2020 Apr; 8(4):359-367. PubMed ID: 31839558 [TBL] [Abstract][Full Text] [Related]
18. Sustainability of a 12-month lifestyle intervention delivered by community health workers in reducing blood pressure in Nepal: 5-year follow-up of the COBIN open-label, cluster randomised trial. Thapa R; Zengin A; Neupane D; Mishra SR; Koirala S; Kallestrup P; Thrift AG Lancet Glob Health; 2023 Jul; 11(7):e1086-e1095. PubMed ID: 37349035 [TBL] [Abstract][Full Text] [Related]